These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 15373062)

  • 1. [Maintaining independence. New protease inhibitor receives drug approval recommendation].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():84-5. PubMed ID: 15373062
    [No Abstract]   [Full Text] [Related]  

  • 2. [Long-term virus suppression. Expanding therapy options with protease inhibitor].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():68-9. PubMed ID: 16385882
    [No Abstract]   [Full Text] [Related]  

  • 3. FDA approves Lexiva.
    IAPAC Mon; 2003 Nov; 9(11):280. PubMed ID: 14989187
    [No Abstract]   [Full Text] [Related]  

  • 4. FDA notifications. FDA approves NDA for Lexiva.
    AIDS Alert; 2007 Dec; 22(12):142. PubMed ID: 18415960
    [No Abstract]   [Full Text] [Related]  

  • 5. Lower dose of ritonavir approved for use with fosamprenavir.
    Sax PE
    AIDS Clin Care; 2007 Dec; 19(12):106. PubMed ID: 18399004
    [No Abstract]   [Full Text] [Related]  

  • 6. FDA notifications. FDA approves new formulation of Lexiva.
    AIDS Alert; 2007 Aug; 22(8):90-1. PubMed ID: 17768778
    [No Abstract]   [Full Text] [Related]  

  • 7. Four posters add to our knowledge of Lexiva.
    Proj Inf Perspect; 2008 Dec; (47):7-8. PubMed ID: 19227558
    [No Abstract]   [Full Text] [Related]  

  • 8. [Are all boosted protease inhibitors the same? Previously treated patients profit too from lopinavir/r].
    MMW Fortschr Med; 2003 Dec; 145(50):61. PubMed ID: 14963981
    [No Abstract]   [Full Text] [Related]  

  • 9. [Individualized therapy with fosamprenavir/r. A PI suitable in liver problems].
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():60-1. PubMed ID: 19031566
    [No Abstract]   [Full Text] [Related]  

  • 10. [FPV plus SQV plus a mini-dose ritonavir. "Double boosting with compatible partners].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():92-3. PubMed ID: 15373070
    [No Abstract]   [Full Text] [Related]  

  • 11. Agenerase approved by FDA.
    Gaylord G
    Posit Living; 1999 May; 8(4):6. PubMed ID: 12492061
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fosamprenavir (GW433908)/ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program.
    Pérez-Elias MJ; Sánchez-Conde M; Soriano V; Mallolas J; Luque I; Rodríguez-Alcántara F;
    Enferm Infecc Microbiol Clin; 2009 Jan; 27(1):28-32. PubMed ID: 19218000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fosamprenavir: drug development for adherence.
    Hester EK; Chandler HV; Sims KM
    Ann Pharmacother; 2006; 40(7-8):1301-10. PubMed ID: 16757678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fosamprenavir: a new PI option. Interview by Craig Sterritt.
    Nadler J
    IAPAC Mon; 2004 Feb; 10(2):50-2. PubMed ID: 15106520
    [No Abstract]   [Full Text] [Related]  

  • 16. Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials.
    Marcelin AG; Flandre P; Molina JM; Katlama C; Yeni P; Raffi F; Antoun Z; Ait-Khaled M; Calvez V
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4251-7. PubMed ID: 18852278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Potent new protease inhibitor. Boostered protease inhibitors--a separate class of drugs].
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():40-1. PubMed ID: 15011585
    [No Abstract]   [Full Text] [Related]  

  • 18. Amprenavir study results released.
    AIDS Patient Care STDS; 1999 Dec; 13(12):754. PubMed ID: 10743545
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir.
    Masquelier B; Assoumou KL; Descamps D; Bocket L; Cottalorda J; Ruffault A; Marcelin AG; Morand-Joubert L; Tamalet C; Charpentier C; Peytavin G; Antoun Z; Brun-Vézinet F; Costagliola D;
    J Antimicrob Chemother; 2008 Jun; 61(6):1362-8. PubMed ID: 18390885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA grants approval to fosamprenavir calcium.
    AIDS Alert; 2004 Jan; 19(1):11-2. PubMed ID: 14974421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.